 David Wagner
Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| CD40 Antigens | 21 | 2023 | 88 | 6.940 |
Why?
| | CD40 Ligand | 9 | 2023 | 38 | 1.820 |
Why?
| | CD4-Positive T-Lymphocytes | 10 | 2024 | 1044 | 1.770 |
Why?
| | Diabetes Mellitus, Type 1 | 14 | 2024 | 3604 | 1.540 |
Why?
| | T-Lymphocyte Subsets | 5 | 2019 | 411 | 1.390 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 2 | 2019 | 57 | 1.140 |
Why?
| | Multiple Sclerosis | 3 | 2022 | 428 | 1.130 |
Why?
| | Mice, Inbred NOD | 14 | 2019 | 579 | 1.090 |
Why?
| | Autoimmunity | 8 | 2014 | 861 | 1.010 |
Why?
| | Peptides | 3 | 2023 | 904 | 0.990 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2017 | 137 | 0.950 |
Why?
| | Autoimmune Diseases | 3 | 2024 | 421 | 0.880 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 1 | 2022 | 25 | 0.800 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2022 | 70 | 0.760 |
Why?
| | T-Lymphocytes | 5 | 2013 | 1913 | 0.710 |
Why?
| | Forkhead Transcription Factors | 2 | 2013 | 182 | 0.670 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 3 | 2017 | 332 | 0.630 |
Why?
| | Therapies, Investigational | 1 | 2018 | 14 | 0.600 |
Why?
| | Mice | 20 | 2024 | 16583 | 0.560 |
Why?
| | Oligopeptides | 1 | 2019 | 256 | 0.560 |
Why?
| | Signal Transduction | 8 | 2023 | 4867 | 0.550 |
Why?
| | Cell Movement | 3 | 2017 | 935 | 0.520 |
Why?
| | Demyelinating Diseases | 1 | 2017 | 83 | 0.520 |
Why?
| | Central Nervous System | 1 | 2017 | 254 | 0.470 |
Why?
| | Animals | 23 | 2024 | 34708 | 0.470 |
Why?
| | Flow Cytometry | 7 | 2017 | 1147 | 0.430 |
Why?
| | Cytokines | 4 | 2017 | 1997 | 0.420 |
Why?
| | fas Receptor | 1 | 2013 | 96 | 0.420 |
Why?
| | CTLA-4 Antigen | 2 | 2012 | 88 | 0.400 |
Why?
| | Galectins | 1 | 2012 | 22 | 0.390 |
Why?
| | Biomedical Research | 1 | 2018 | 654 | 0.390 |
Why?
| | Membrane Microdomains | 2 | 2010 | 32 | 0.390 |
Why?
| | DNA-Binding Proteins | 2 | 2013 | 1424 | 0.380 |
Why?
| | Autoantigens | 2 | 2012 | 414 | 0.370 |
Why?
| | Islets of Langerhans | 1 | 2017 | 792 | 0.360 |
Why?
| | Mice, Inbred BALB C | 6 | 2023 | 1230 | 0.350 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2010 | 85 | 0.340 |
Why?
| | Epitopes | 1 | 2012 | 469 | 0.340 |
Why?
| | CD4 Antigens | 2 | 2008 | 137 | 0.340 |
Why?
| | Homeodomain Proteins | 1 | 2013 | 480 | 0.330 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2010 | 163 | 0.330 |
Why?
| | Cell Proliferation | 5 | 2017 | 2344 | 0.320 |
Why?
| | Adoptive Transfer | 3 | 2017 | 217 | 0.310 |
Why?
| | Immune Tolerance | 2 | 2012 | 349 | 0.310 |
Why?
| | TNF Receptor-Associated Factor 2 | 1 | 2008 | 8 | 0.300 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2008 | 377 | 0.300 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 76 | 0.300 |
Why?
| | Platelet Membrane Glycoprotein IIb | 1 | 2007 | 4 | 0.290 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2013 | 703 | 0.270 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 2006 | 15 | 0.270 |
Why?
| | Interferon-gamma | 3 | 2017 | 759 | 0.270 |
Why?
| | Biomarkers | 3 | 2024 | 3878 | 0.240 |
Why?
| | Spleen | 3 | 2017 | 518 | 0.230 |
Why?
| | Hospitals, Animal | 1 | 2024 | 3 | 0.230 |
Why?
| | Trypanosoma cruzi | 1 | 2023 | 24 | 0.210 |
Why?
| | Hospitals, Teaching | 1 | 2024 | 112 | 0.210 |
Why?
| | Genes, RAG-1 | 1 | 2003 | 11 | 0.210 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 1 | 2023 | 31 | 0.210 |
Why?
| | Chagas Disease | 1 | 2023 | 33 | 0.210 |
Why?
| | Dogs | 1 | 2024 | 372 | 0.200 |
Why?
| | Integrins | 1 | 2023 | 94 | 0.200 |
Why?
| | Inflammation | 2 | 2024 | 2696 | 0.200 |
Why?
| | Blotting, Western | 2 | 2017 | 1189 | 0.190 |
Why?
| | Immunomodulation | 2 | 2012 | 90 | 0.180 |
Why?
| | Leukocytes, Mononuclear | 1 | 2024 | 543 | 0.180 |
Why?
| | Mice, Inbred C57BL | 5 | 2019 | 5282 | 0.180 |
Why?
| | Mice, SCID | 2 | 2017 | 340 | 0.170 |
Why?
| | Diabetes Mellitus | 1 | 2008 | 991 | 0.160 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2523 | 0.160 |
Why?
| | Lymphocyte Activation | 2 | 2017 | 1094 | 0.160 |
Why?
| | Amino Acids | 1 | 2023 | 470 | 0.160 |
Why?
| | CD28 Antigens | 2 | 2017 | 48 | 0.160 |
Why?
| | Mice, Knockout | 2 | 2017 | 2774 | 0.150 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2021 | 202 | 0.150 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2019 | 174 | 0.150 |
Why?
| | Female | 10 | 2021 | 68274 | 0.140 |
Why?
| | Freund's Adjuvant | 1 | 2017 | 17 | 0.140 |
Why?
| | Phenotype | 2 | 2017 | 3062 | 0.140 |
Why?
| | Cell Survival | 2 | 2012 | 1085 | 0.140 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2017 | 48 | 0.140 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 760 | 0.140 |
Why?
| | Immunologic Memory | 1 | 2019 | 337 | 0.130 |
Why?
| | Cell Separation | 2 | 2014 | 312 | 0.120 |
Why?
| | Lymph Nodes | 1 | 2017 | 459 | 0.120 |
Why?
| | Disease Models, Animal | 2 | 2017 | 3999 | 0.120 |
Why?
| | Precision Medicine | 1 | 2018 | 386 | 0.110 |
Why?
| | Spinal Cord | 1 | 2017 | 360 | 0.110 |
Why?
| | Cell Division | 2 | 2008 | 802 | 0.110 |
Why?
| | Humans | 10 | 2024 | 129078 | 0.110 |
Why?
| | Ku Autoantigen | 1 | 2013 | 13 | 0.110 |
Why?
| | Antigens, Nuclear | 1 | 2013 | 20 | 0.110 |
Why?
| | Thymocytes | 1 | 2013 | 30 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1005 | 0.110 |
Why?
| | HLA-DR Antigens | 1 | 2014 | 226 | 0.100 |
Why?
| | Peptide Fragments | 1 | 2017 | 694 | 0.100 |
Why?
| | Interleukin-17 | 1 | 2013 | 107 | 0.100 |
Why?
| | Mice, Transgenic | 2 | 2012 | 2082 | 0.100 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2012 | 30 | 0.100 |
Why?
| | Haplotypes | 1 | 2014 | 473 | 0.100 |
Why?
| | Receptors, Virus | 1 | 2012 | 81 | 0.100 |
Why?
| | Protein Transport | 1 | 2013 | 424 | 0.100 |
Why?
| | RNA, Messenger | 2 | 2013 | 2702 | 0.090 |
Why?
| | Leukocyte Common Antigens | 1 | 2011 | 81 | 0.090 |
Why?
| | Disease Progression | 2 | 2017 | 2607 | 0.090 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2014 | 258 | 0.090 |
Why?
| | NF-kappa B | 2 | 2008 | 687 | 0.090 |
Why?
| | Brain Ischemia | 1 | 2014 | 308 | 0.090 |
Why?
| | Interleukin-2 | 1 | 2012 | 428 | 0.090 |
Why?
| | Cell Nucleus | 1 | 2013 | 571 | 0.090 |
Why?
| | Benzimidazoles | 1 | 2011 | 158 | 0.090 |
Why?
| | Heart Arrest | 1 | 2014 | 327 | 0.090 |
Why?
| | Prediabetic State | 1 | 2013 | 242 | 0.080 |
Why?
| | Glycosylation | 1 | 2010 | 144 | 0.080 |
Why?
| | Molecular Weight | 1 | 2010 | 332 | 0.080 |
Why?
| | Bleomycin | 1 | 2011 | 241 | 0.080 |
Why?
| | Down-Regulation | 1 | 2012 | 639 | 0.080 |
Why?
| | DNA Primers | 1 | 2010 | 522 | 0.080 |
Why?
| | Protein Isoforms | 1 | 2010 | 370 | 0.080 |
Why?
| | bcl-X Protein | 1 | 2008 | 41 | 0.070 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2008 | 21 | 0.070 |
Why?
| | Magnetics | 1 | 2008 | 44 | 0.070 |
Why?
| | Receptors, Chemokine | 1 | 2007 | 46 | 0.070 |
Why?
| | Protein Binding | 1 | 2013 | 2087 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2006 | 1858 | 0.070 |
Why?
| | Pulmonary Fibrosis | 1 | 2011 | 381 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2012 | 4063 | 0.070 |
Why?
| | Cell Death | 1 | 2008 | 344 | 0.070 |
Why?
| | Time Factors | 1 | 2017 | 6579 | 0.070 |
Why?
| | HIV Infections | 1 | 2021 | 2699 | 0.070 |
Why?
| | Base Sequence | 1 | 2010 | 2157 | 0.070 |
Why?
| | Antigens, CD | 1 | 2008 | 480 | 0.060 |
Why?
| | HLA Antigens | 1 | 2007 | 236 | 0.060 |
Why?
| | Adolescent | 3 | 2021 | 20241 | 0.060 |
Why?
| | Brain | 1 | 2017 | 2604 | 0.060 |
Why?
| | Homeostasis | 1 | 2008 | 605 | 0.060 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 2003 | 12 | 0.050 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2003 | 21 | 0.050 |
Why?
| | Amino Acid Sequence | 1 | 2007 | 2050 | 0.050 |
Why?
| | Mice, Inbred C3H | 1 | 2023 | 279 | 0.050 |
Why?
| | Clone Cells | 1 | 2003 | 258 | 0.050 |
Why?
| | DNA, Complementary | 1 | 2003 | 270 | 0.050 |
Why?
| | Young Adult | 2 | 2021 | 12310 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2846 | 0.050 |
Why?
| | Double-Blind Method | 1 | 2007 | 1864 | 0.050 |
Why?
| | Cloning, Molecular | 1 | 2003 | 536 | 0.050 |
Why?
| | Pancreas | 1 | 2004 | 307 | 0.050 |
Why?
| | Adult | 3 | 2021 | 35423 | 0.050 |
Why?
| | Th1 Cells | 1 | 2002 | 135 | 0.050 |
Why?
| | North Carolina | 1 | 2021 | 91 | 0.050 |
Why?
| | Thymus Gland | 1 | 2002 | 307 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2021 | 172 | 0.040 |
Why?
| | Middle Aged | 2 | 2014 | 31024 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2007 | 3336 | 0.040 |
Why?
| | Male | 4 | 2021 | 63248 | 0.040 |
Why?
| | Lung | 1 | 2011 | 3925 | 0.040 |
Why?
| | Universities | 1 | 2021 | 404 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2008 | 2116 | 0.030 |
Why?
| | Students | 1 | 2021 | 576 | 0.030 |
Why?
| | Aged | 1 | 2014 | 22068 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2014 | 311 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2021 | 1264 | 0.030 |
Why?
| | Cytological Techniques | 1 | 2011 | 25 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2011 | 197 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5036 | 0.020 |
Why?
| | Hippocampus | 1 | 2014 | 791 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 5365 | 0.020 |
Why?
| | Lung Injury | 1 | 2011 | 214 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1045 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2008 | 299 | 0.020 |
Why?
| | Up-Regulation | 1 | 2008 | 850 | 0.020 |
Why?
| | Models, Statistical | 1 | 2008 | 627 | 0.010 |
Why?
| | Software | 1 | 2008 | 612 | 0.010 |
Why?
| | Cell Line | 1 | 2008 | 2762 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2008 | 1361 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 2011 | 1878 | 0.010 |
Why?
| | Cohort Studies | 1 | 2008 | 5400 | 0.010 |
Why?
|
|
Wagner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|